Особенности диагностики и лечебной тактики у пациентов с семейными формами гипертрофической кардиомиопатии
Диссертация
Самым доступным и верным методом диагностики, позволяющим верифицировать диагноз ГКМП и демонстрирующим как диффузную, так и сегментарную гипертрофию миокарда, является двухмерная эхокардиография. Основным диагностическим признаком ГКМП является ассиметричное утолщение стенки ЛЖ, толщина которой может быть в 1,5−3 раза больше толщины задней стенки ЛЖ и превышает 15 мм. По данным двухмерной… Читать ещё >
Список литературы
- Амосова, Е.Н. Кардиомиопатии / Амосова Е. Н. // «Книга плюс», Киев.-1999.-С.161−170.
- Белоконь, Н.А. Болезни сердца и сосудов у детей. Руководство для врачей в двух томах / Белоконь Н. А., Кубергер М. Б. // М.: «Медецина».-1987.- Т.1.-С.448.
- Бокерия, JI.A. Риск внезапной сердечной смерти у больных гипертрофической кардиомиопатии / Бокерия JI.A., Борисов К. В., Савченко Е. Д. // Грудная и сердечно -сосудистая хирургия.-2001.-№ 1.-С.62−66.
- Бокерия, JI.A., Оригинальный способ хирургического лечения гипертрофической обструктивной кардиомиопатии / Бокерия JI.A., Борисов К: В., Синев А. Ф. // Грудная и сердечно -сосудистая хирургия.-1998.-Т.2.-С4−10.
- Бокерия, JI.A. Хирургическое лечение среднежелудочковой обструкции у пациентов с среднежелудочковой формой ГОКМП / Бокерия Л. А., Борисов К. В., Синев А. Ф., Прелатова Ю. В. // Бюл. НЦССХ им. А. Н. Бакулева РАМН.-2005.-№ 6.-С.123.
- Бокерия, Л.А. Хирургическая коррекция ранее неоперабельных форм гипертрофической обструктивной кардиомиопатии / Бокерия Л. А., Борисов К. В., Синев А. Ф., Шевердина В. В. // Грудная и сердечнососудистая хирургия.- 1999.-№ 6.-С. 13 0−136.
- Бухарин, В.Ф. Клиника, диагностика и лечение идиопатического субаортального стеноза / Бухарин В. Ф., Петросян Ю. С., Иваницкая М. А., Иваницкий А. В., Оводова Н. Ф. // Кардиология.-1975.- № 3.-С.23−30.
- Габрусенко, С.А. Кардиомиопатии: современное состояние проблемы/ Габрусенко С. А. //Болезни сердца и сосудов.-2006.-Т.1.-.№ 1.-С.9−14.
- Гуревич, М.А. Принципы консервативной терапии гипертрофической кардиоимиопатии / Гуревич М. А. // Консилиум-медикум.-2001 .-Т. 1 .-№ 10.С 3−10.
- Джанашия, П.Х. Кардиомиопатии и миокардиты / Джанашия П. Х., Круглов В. А., Назаренко В. А., Николенко С. А. // РГМУ. Москва.-2000.-С.112.
- Доклад Комитета Экстпертов ВОЗ. Кардиомиопатии.- Жененва.-1990.-С.67.
- Журавлева, Н.Б. Эхо- и электрокардиографические признаки различных форм гипертрофической кардиомиопатии / Журавлева Н. Б., Мыслицкая Г. В., Новикова В. Н., ГришкинЮ.Н. // Кардиология.-1984.-С70−73.
- Коровина, Е.П. Гипертрофическая кардиомиопатия.-Клинико-диагностические особенности морфометрических вариантов.- Автореф. Дис.канд.мед.наук. Москва,-1988.
- Кушуковский, М.С. Фибриляция предсердий (причины, механизмы, клинические формы, лечение и профилактика) / Кушуковский М. С. // СПб. ИКФ «Фоллиант». -1999.-С.176.
- Лилли, Л. Патофизиология заболеваний сердечно сосудистой системы / Л. Лилли // Лаборатория знаний. Москва, Бином.-2003.С.305−327.
- Моисеев, B.C., Кардиомиопатии / Моисеев B.C., Сумароков А. В., Стяжкин В. Ю. // Москва. Медецина.-1993.
- Мухарлямов, Н.М. Кардиомиопатии / Мухарлямов Н. М. // Москва. Медицина.-1990.
- Оводова, Н.Ф. Обструктивная гипертрофическая кардиомиопатия(клиника, диагностика, лечение) / Оводова Н. Ф // Автореф. Дис.докт.мед.наук.М.-1984.I
- Оводова, Н.Ф. Клиническая диагностика субаортального стеноза и оценка методов лечения / Оводова Н. Ф, Митина И. Н. // Кардиология.- 1978.-№ 9.~ С.79−83.
- Орешина, Т.В. Морфо-функциональные параметры сердца и некоторые генетические показатели у больных с семейными и спорадическими формами гипертрофической кардиомиопатии / Орешина Т. В. // Дис., канд.мед.наук.-2004.
- Поляков, В.П. Кардиологическая практика: руководство для врачей в двух томах / Поляков В. П., Мовшович Б. Л., Савельева Г. Г. //Т.2.-1993.
- Прелатова, Ю.В. Особенности Эхокардиографической диагностики и оценка эффективности лечения у пациентов с среднежелудочковой формой гипертрофической кардиомиопатии / Прелатова Ю. В. // Дис., канд.мед.наук.-2004.
- Ройтберг, Т.Е. Внутренние болезни сердечно сосудистой системы / Ройтберг Т. Е., Струтынский А. В. // Москва. Издательство Бином.-2003.1. C.751−761.
- Савченко, Е.Д. Гипертрофическая обструктивная кардиомиопатия с обструкцией правого и левого желудочков. Сравнение результатов медикаментозного и хирургического лечения / Савченко Е. Д. // Дис., канд.мед.наук.-2007.
- Целуйко, В.И. Генетический аспект гипертрофической кардиомиопатии / Целуйко В. И. // Кардиология.-1998.-№ 6.-С.63−66.
- American College of Cardiology European Society of Cardiology Clinical Expert Document of Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology.-2003.-Vol.42.-№ 9.
- Basso, C. Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia / Basso C., Thienne G., Corrado
- D., et.al. // Hum. Pat.-2000.-31.-988−88.
- Bonow RO, Dilsizian V, Rosing DR et al. Circulation 1985- 72: 853−64.
- Bonow R.O., Frederick R.M., Bacharach S.L., et.al. Atrial systole and left ventricular filling in hypertrophic cardiomyopathy: effect of verapamil. J. 1983−51:1386−1391.
- Bonow R.O., Vitale D.P., Maron B.J., et.al. Regional left ventricular asynchrony and impaired global ventricular filling in hypertrophic cardiomyopathy: effect of verapamil. J. Am. Col. Cardiol. 1987: 9: 1108−1116.
- Borggrefe M., Schwammenthal E., Block M., Schulte H.D. Pre and postoperative electrophysiologic findings in survivors of cardiac arrest and hypertrophic cardiomyopathy undergoing myectomy. Circulationl 993−88(suppl):I-210. Abstract.
- Boriani G, Rapezzi C, Biffi M et al. J Cardiovasc Electrophysiol 2002- 13: 954.
- Brigden W. Uncommon myocardial disease. The non- coronary cardio myopathies. Lancet 1957−2:1179.
- Brutsaert D.L., Rademakers F.E., Sys SU. Triple control of relaxation: implication in cardiac disease. Circulation. 1980- 69:190−96.
- Burton D, Abdularazzak H, Knott A. Two mutations in troponin I that cause haypertrophic cardiomyopathy have contrasting effect on cardiac muscle contractility // Bilchemical J.-2002.-Vol.362.-P.443−451.
- Camerini F., Gavacci A., De Maria R. Advances in cardiomyopathies. Springer Verlad/ Italia / Milano / 1998-P: 72−76.
- Cannon R.O., Dilsizian V., O’Gara P.T., et.al. Myocardial metabolic, hemodynamic and electrocardiographic significance of reversible thallium — 201 abnormalities in hypertrophic cardiomyopathy. Circulation. 1991 -83:1660−1667.
- Cecchi F., et.al. Prognostic value of non- sustainad ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population. Heart 1998−79:331−336.
- Cecchi F., Olivotto I. New concepts in hypertrophic cardiomyopathies. Circulation.2002- 105: 188.
- Cecchi F.I., Olivotto I.P. The new England Journal of Medicin 2003−349:1027−1035.
- Cecchi F, Olivotto I, Gistri R et al. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 2003.
- Cohen LS, Braunwald E. Circulation 1967- 35: 847−51.
- Dilsizian V, Bonow RO, Epstein SE, Fananapazir L. J Am Coll Cardiol 1993- 22: 796−804.
- Dimitrow PP, Krzanowski M, Nizankowski R et al. Cardiovasc Drugs Ther 2000- 14 (6): 643−50.
- Elliott P.M., Gimeno Blanes J.R., Mahon N.G., et.al. Relation between severity of left ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet.2001−3 57:420−424.
- Elliott P.M., Polonieckis, Dickie S. Hypertrophic cardiomyopathy: identification of high risk sudden death in patients. Am.J. Col. Cardiol 2000−36:2212−8.
- Elliott PM, Poloniecki J, Dickie S et al. J Am Coll Cardiol 2000- 36: 2212−18.
- Epstein S.E., Rosing D.R. Verapamil: its potential for causing serious complication in patients with hypertrophic cardiomyopathy. Circulation: 1981−64:437−441.
- Erdmann J, Raible J, Maki-Abadi J. Spectrum of clinical phenotypes and gene variants in cardiac myosin-binding protein С mutation carriers with hypertrophic cardiomyopathy // J American College of Cardiol ogy.-2001.-Vol.38.-P.322−330.
- Falicov R.E., Resnekov L., Bharati S., Lev M. Midventricular obstruction: a variant of obstructive cardiomyopathy. Am J Cardiol. 1976- 37: 432−437.
- Fananapazir L. J. Advances in molecular genetics and management of hypertrophic cardiomyopathy clinical conference. [published erratum appears in JAMA 1999 Dec 22−29- 281 (24): 2303] [see comments]. JAMA 1999- 281 (18): 1746−52.
- Fananapazir L, Cannon R.O., Tripodi D., et al. Impact of dual-chamber permanent pacing in patients with obstructive hypertrophic cardiomyopathy with symptoms refractory to verapamil and B-adrenergic blocker therapy. Circulation. 1992- 85: 2149−2161.
- Fatkin D, Graham R. Molecular Mecjanisms if Inherited Cardiomyopathies // Physiology Review.-2002.-Vol.82.-P.945−980.
- Fay W.P., Taliercio C.P., Ilstrup D.M., et.al.Natural history of hypertrophic cardiomyopathy in the elderly. J Am Coil Cardiol. 1990- 16:821−826.
- Feber L., Seggewiss H., Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: result with respect to intraprocedural myocardial contract echocardiography. Circulation. 1998- Dec 1−98 (22):2415−21.
- Ferraus V.J., Morrow A.G., Roberts W.C. Miocardial ultrastructure in hypertrophic subaortic stenosis.
- Figali S., Krajcer Z., Edelman. Progression of hypertrophic cardiomyopathy intj hypokinetic left ventricle higher incidence in patients with midventricular obstruction. J. Am. Col. Car. Feb.9 (2):288−94.
- Frank S., Brounwald E., Idiopatic hypertrophic subaortic stenosis: clinical analisis of 126 path, with emphasis of natural history. Circul.1986- 37: 759−88.
- Gaasch W.H., Levine H.J., et. al. Left ventricular compliance mechanisms and clinical implications. Am.J. Col. Cardiol. 1976- 38:645−65.
- Geisterfer-Lowrance A, Kasss S, Tanigava G. A molecular basis for familial hypertrophic cardiomyopathy: a b cardiac myosin heavy chain missense mutation // Cell.-1990.-Vol.62.-P.999−106.
- Gilligan DM, Chan WL, Joshi J et al. J Am Coll Cardiol 1993- 21: 1672−9.
- Gistri R, Cecchi F, Choudhury L et al. Am J Cardiol 1994- 74: 363−8.
- Glancy D.L., O’Brien K.P., Gold H.K., Epstain S.E. Atrial fibrillation in patients with idiopathic hypertrophic subaortic stenosis. 1970−32:652−659.
- Greenspan A.M. Hypertrophic cardiomyopathy and atrial fibrillation: a change of perspective. JACC 1990- V.15-№ 6- 1286−7.
- Grossman W., McLaurin L.R. Diastolic properties of then left ventricle. A Intern.Med.l 979−84:316−326.
- Harrison D.C., Braunwald E., Gliek G., et. al. Effekts of beta adrenergic blockade on the circulation with particular reference to observation in patients with hypertrophic subaortic stenosis. Circulationl964−29:84−98.
- Hess OM. J Am Coll Cardiol 2003- 42 (5): 880−1. Dilsizian V, Bonow RO, Epstein SE, Fananapazir L. J Am Coll Cardiol 1993- 22: 796−804.
- Klues H.G., Roberts W.C., Maron B.J. Anomalous insertion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy: significance in producing left ventricular outflow obstruction. Circulation. 1994−84: 1188−1197.
- Korovina EP. Klin Med (Mosk) 1998- 76 (12): 30−5.
- Leyer H.M., Karam R.F., Currie P.J., Healy B.P. Hypertrophic cardiomyopathy in the elderly: distinctions from the young based on cardiac shape. Circulation. 1989−79:580−589.
- Louie EK, Edwards LC. Prog Cardiovasc Dis 1994- 36: 275−308.
- Marian A. J., Nishimura R.A., Cesey S., Development of the left ventricle hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin- binding protein С gene mutations. JACC 2001- 38: 315−21.
- Marian A.J., Roberts R. Recept advances in the molecular genetigs of hypertrophic cardiomyopathy. Circ. 1995- 92: 1336−1347.
- Marian A. J., Roberts R. The molecular genetic basis forhypertrophic cardiomyopathy. J Cardiovase Electrophysiol. 1998- 9: 88−99.
- Marian A.J., Roberts R. The molecular genetic basis forhypertrophic cardiomyopathy. Journal of molecular and cellular cardiology/ 2001−33:655−670.
- Maron BJ. Hypertrophic cardiomyopathy. Lancet 1997- 350: 127−33.
- Maron B.J. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002- 287: 1308−20.
- Maron B.J., et al. Prevalence of hypertrophic Cardiomyopathy in a general population of young adults. Echocardiographic analisis of 4111 subjects in the CARDIA study. Circulation 1995- 92: 785−789.
- Maron B.J., Bonow R.O., Cannon R.O.III et. al. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy. N. Eng. J. Med. 1987- 316:844−52.
- Maron BJ, Casey SA, Hauser RG, Aeppli DM. Clinical course of hypertrophic cardiomyopathy with survival to advanced age. J Am Coll Cardiol 2003- 42 (5): 882−8.
- Maron BJ, Casey SA, Poliac LC et al. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999- 281: 650−5.
- Maron B.J., Gottdiener J.S., Epstain S.E. Patterns and significance of distribution of left ventricle hypertrophy in hypertrophic cardiomyopathy. A wide- angle, two- dimensional echocardiography study ofl25 path. J.Am.Car.48:418−428.
- Maron B.J., Kogan J., Proschan M.A. Circadian varibbility in the occurrence of sudden death in patients with hypertrophic cardiomyopathy. JACC 1994- 14 059.
- Maron B.J., Mark Estes III NA, et.al. Primary preventions of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. JACC. 1994- 1405−9.
- Maron BJ, Morrow A.G., Epstein S.E. Symptomatic status and prognosis of patients after operation for obstructive hypertrophic cardiomyopathy: efficacy of ventricular septal myotomy and myectomy. Eur. Heart J. 1983: 4 (suppl F):175−185.
- Maron BJ, Nishimura R.A., Danielson. Pitfalls in clinical recognition fed a novel operative approach for hypertrophic cardiomyopathy with severe outflow obstruction due to anomalous papillary muscle. Circulation. 1998−98:2505−8.
- Maron B.J., Olivotto I., Spirito P., et.al. Epidemiology of hypertrophic cardiomyopathy — related death. Revisited in a Large Non- Referral- Based Patient Population. Circulation. 2002−102(8):858−864.
- Maron BJ, Peterson EE, Maron MS, Peterson JE. Prevalence of hypertrophic cardiomyopathy in an outpatients population reffered for echocardiographic study. Am J Cardiol 1994- 73: 533−80.
- Maron BJ, Roberts W.C., et.al. Sudden death in young athletes. Circulationl980-vol.61:218−229.
- Maron B.J., Roberts W.C. Quantative analyses cardiac muscle: sell disorganization in the ventricular septum of patients with hypertrophic cardiomyopathy. Circul. 1979- 59: 689−706.
- Maron BJ, Roberts WC, Epstein SE. Circulation 1982- 65: 1388−94.
- Maron B.J., Savage D.D., Wolfson J.K., Epstain S.E. Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study. Am J. Cardiol. 1981- 48: 252−257.
- Maron BJ, Shen W-K, Link MS et al. N Engl J Med 2000- 342: 365−73.
- Maron BJ, Spirito P., Greene KJ, et al. Nonivasive assessment of left ventricular diastolic function by pulsed Doppler echocardiography in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1987- 10:733−742.
- Maron B.J., Wolfson J.K., Epstain S.E., et.al. Intramural «small vessel» coronary artery disease in hypertrophic cardiomyopathy. JACC 1986−8:545−57.
- Maron B.J., Wolfson J, Roberts W. Relation between extent of cardiac muscle cell disorganization and left ventricular wall thickness in hypertrophic cardiomyopathy // American J of cardiology.- 1992.-Vol.70.-P.785−790.
- Maron В.J., Roberts W.C., EpsteinS.E. Sudden death in hypertrophic cardiomyopathy: a profile in 78 patients. Circulation. 1982−65:13 88−1394.
- McCully В Robert, Rich A., Nishimura, Jamil Tajik, et.al. Extent of Clinical Improvement After Surgical Treatment of Hypertrophic obstructive cardiomyopathy. Circulation. 1996−94:467−471.
- Mcintosh C.L., Maron В J, Current operative treatment of obstructive hypertrophic cardiomyopathy. Circulationl988−78:487−495.
- McKenna W.J., Behr E.R. Hypertrophic cardiomyopathy: management, risk stratification and prevention of sudden death. Heart 2002−87:169−176.
- McKenna W.J., Deanfield J., Faruqui A., et.al. Prognosis in hypertrophic cardiomyopathy: role of age, and clinical, electrocardiographic and hemodynamic features. Am J Cardiol. 1981−47:532−538.
- McKenna W.J., England D., Doi YL, et.al. Arrhythmia in hypertrophic cardiomyopathy, Influence on prognosis. Br. Heart J.1981−46:168−172.
- McKenna WJ., Harris L., Rowland E., et.al. Amiodarine for long- term management of patients with hypertrophic cardiomyopathy. Am J Cardiol. 1984−54:802−810.
- McKenna WJ, Oakley CM, Krikler DM, Goodwin JF. Br Heart J 1985- 53- 412−6.
- Michele D, Gomez C, Hong K. Cardiac dysfunction in hypertrophic cardiomyopathy mutant tropomyosin mice is transgene-dependent, hypertrophy-independent, and improved by b-blockade // Circulation research.-2002.-Vol.91.-P.255−262.
- Mogrnsen J, Klausen lb, Pedersen A. a-cardiac actin in a novel disease gene in familial hypertrophic cardiomyopathy // J of Clinical Investigations.-1999.-Vol. 103 .-P.R39-R43.
- Mogensen J, Kubo T, Duque M. Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations // J of Clinical Investigation.-2003 .-Vol. 111 .-P.209−216.
- Mohr R., Schaff H.V., Danielson G.K., et.al. The outcome of surgical treatment of hypertrophic obstructive cardiomyopathy: experience over 15 years. J Thorac Cardiovasc Surg. 1989−97:666−674.
- Monserrat L, Elliott PM, Gimeno Ж et al. Non-sustained ventricular tachicardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol 2003- 42 (5): 873−9.
- Moolman J, Corfield V, Posen B. Sudden death due to troponin T mutations // J of American College of Cardiology.-1997.-Vol.29.-P.549−555.
- Morrow A.G., Brockenbrough E.C., Surgial treatment of idiopathic hypertophic subaortic stenosis: technic and hemodynamic result of subaortic ventriculomyotomy. Ann Surg. 1961- 154:181−189.
- Nayler W.C., Williams A. Relaxation in heart musculce: some morphological and biochemical cociderations. Fur. J. Car. 7(suppl)35−50.
- Niimura H, Bachinski L, Sangwatanatori S. Mutations in the gene for cardiac myosin-binding protein С and late-onset hypertrophic cardiomyopathy // New England J of Medicine .-1998.-Vol.338.-P. 1248−57.
- Niimura H., Patton K.K., McKenna W.J., et. al. Sarcomere protein gene mutation in hypertrophic cardiomyopathy of the eldery. Circul. 2002- 105: 44 651.
- Olivotto I., MD, Franco Cecchi, MD, et. al. Impact of atrial fibrillation on clinical course of hypertrophic cardiomyopathy. Circulation 2001- 104:2517.
- Olson T, Doan T, Kishimoto N. Inherited and de novo mutations in the cardiac actin gene causes hypertrophic cardiomyopathy // J Molecular and Cellular Cardiology.-2000.-Vol.32.-P. 1687−1694.
- Ommen S.R., Nishimura R.A. A Physicians Guide to the Treatment of the Hyperthrophic Cardiomuopathy. Heart Views. // 2000. Vol. 1.-393−401
- Ommen S.R., Tajik A.J. Hypertrophic cardiomyopathy. Circulation.2001- 104:126.
- Ostman-Smith I, Wettrell G, Riesenfeld T. J Am Coll Cardiol 1999- 34: 1813— 22.
- Paz R., Jortner R., Tunick D.A. The effect of the ingestion of ethanol on obstruction of the left ventricle outflow tract of hypertrophic cardiomyopathy. N.Engl. J. Med. 1996- 335: 938 -41.
- Pollick C. et.al. Muscular subaortic stenosis: the quantitative relationship between systolic anterior motion and the pressure gradient. Circulationl984−69: 43−49.
- Potter K, Hassanzadeh S, Master S. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle //Nature Genetics.-1996.-Vol.13.-P.63−69.
- Regitz-Zagrosek V, Erdmannn J, Weellenhofer E. Novel mutation in the a-tropomyosin gene and transition from hypertrophic to hypocantractile dilated cardiomyopathy // Circulation.-2000.-Vol.l02.-e.l 12-e.l 16.
- Report of the WHO/ ISFC Task Force on the Definition and Classification of Cardiomiopathies. Br. Heart J. 1980−44,672−3.
- Report of the American Collage of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J 2003- 24: 1965−91.
- Richard P, Charron P, Carrier L. Hypertrophic cardiomyopathy. Distribution of disease genes, spectrum of mutations and inplications for a molecular diagnosis strategy // Circulation.-2003.-Vol.l07.-P.2227−2232.
- Roberts R., Sigwart U. New concepts in hypertrophic cardiomyopathies, past II. Circulation.2001- 104(18): 2249- 2252.
- Rosenberg V.D., Nepomnyaschikh L.M. Pathomorphologocal variants of medventricular obstructine of interventricular septum during hypertrophic cardiomyopathies. Bull. Biol. Med. 2004-June 137(6):614−8.
- Rosing DR, Condit JR, Maron BJ et al. Am J Cardiol 1981- 48: 545−53.
- Satoh M, Hayashi T, Nishi H. Titin mutations as the molecular basis for dilated cardiomyopathy // Biochemical and Biophysical Research Communications.-2002.-Vol.291.-P.385−393.
- Satoh M, Takahashi M, Sakamoto T. Structural analysis of the titin gene in hypertrophic cardiomyopathy: identification of a novel disease gene // Biochemical and Biophysical Research Communications.-1999.-Vol.262.-P.411−417.
- Seidman J.G., Seidman C.E. The genetic basis for cardiomyopathy from mutation identification to mechanistic paradigms. Cell2002−104:557−67.
- Seiler C, Hess O.M., Schoebeck M., Turina J., Jenni R., Turina M., Krayenbuehl H. — P. Long-term follow-up of medical versus surgical therapy for hypertrophic cardiomyopathy: a retrospective study. JACC, vol. 17, No 3 1991,634−642.
- Sharma S, Elliott P, Whyte G et al. Am J Cardiol 2000- 86: 162−8.
- Sherrid MV, Gunsburg DZ, Sharma S. Curr Cardiol Rep 2000- 2 (2): 148−53.
- Sherrid M., Pearle G., Gusburg D.Z. Mechanism of benefit of negative inotropes in hypertrophic cardiomyopathy. Circ. 1998−97:41−7.
- Shoudhury L., Mahrhold, Wagner A., et.al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathies. J. Am. Col. Cardiol.2002- 40:2156−64.
- Shwartz K., Carrier L. et. Al. Molecular basis of familial cardiomyopathies.Circ.l995−91: 532−40.
- Solomon SD et al. Left ventricular hypertrophy and morphology in familial hypertrophic cardiomyopathy associated with mutations of the beta-myosin heavy chain gene see comments. J Am Coll Cardiol 1993- 22 (2): 498−505.
- Spirito P., Bellone P., Harris K.M., et. al .Magnitude of left ventricular hypertrophy predicts the risk of sudden death in hypertrophic cardiomyopathy. N Engl. J Med.2000−342:1777−1785.
- Spirito P., Maron B.J.,// JACC.- I990.-Vol. 15, № 7 -P. 1521−1526.
- Spirito P., Maron B.J., Bonow R.O., Epstein SE. Occurrence and significance of progressive left ventricle wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy.A.J.C. 1987−60:123−9.
- Spirito P., Maron В J., Chiarella F., et.al. Diastolic abnormalities in patients with hypertrophic cardiomyopathy: relation to magnitude of left ventricular hypertrophy. Circulation. 1985 vol.72,(2), 310−316.
- Spirito P., Seidman C.E., McKenna WJ. The management of hypertrophic cardiomyoparthy. N.Engl.J.Med.l997−336: 775−85.
- Stafford W.S., Trohman R.G.et. al. Cardac arrest in an adolescent with atrial fibrillation and hypertrophic cardiomyopathy. JACC 1986−7:701−4.
- Stewars S., Mason D.T., Braunwald. Impaired rate of left ventricle filling in idiopathic hypertrophic subaortic stenosis and ventricular aortic stenosis. Circulation. 1968- 37:8−14.
- Sunderson S.E., Gibson D.A., Brown et.al. Left ventricular filling in hypertrophic cardiomyopathy on angiographic study. Br. Heart J. 1997: 39:661−670.
- Teare D. Asymmetric hypertrophy of the heart in young adults. B. Heart J.1958- 20:1−18.
- Theodoro DA, Danielson GK, Feldt RH, Anderson В J. J Thorac Cardiovasc Surg 1996- 112: 1589−97.
- Thierfelder L., Watkins H., MacRae С et. al. Alfa tropomyosin and cardiac troponin T mutation cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell. 1994−77:701−12.
- Toshima H, Koga Y, Nagata H et al. Jpn Heart J 1986- 27: 701−15.
- Varnava A, Elliot P, Baboonian C. Histopathological features of Sudden Death in Cardiac troponin T disease // Circulation.-2001.-Vol.104.-P. 1380−1384.
- Watkins H et al. Sporadic hypertrophic cardiomyopathy due to de novo myosin mutations. J Clin Invest 1992- 90 (5): 1666−71.
- Watkins H., McKenna W.J., Thierfelder L.et.al.Mutation in the genes for cardiac troponin T and alfa tropomyosin in hypertrophic cardiomyopathy. N.Engl. J.Med. 1995−332:1058−64.
- Watkins H. et.al. Sporadic hypertrophic cardiomyopathy due to de novo myosin mytatoin. J. Clin. Invest 1992−90(5): 1666−71.
- Watson D.S., Henry W.L., Maron B.J., Epstain S.E. Effect of operation on left atrial size and the occurrence of atrial fibrillation in patients with hypertrophic subaortic stenosis. Circulation. 1977- 55: 178−181.
- Wigle E.D., The diagnosis of hypertrophic cardiomyopathy. Heart 2001- 86: 709−714.
- Wigle E.D., Adelman A.G., Felderhof C.H. Medical and surgical treatment of Cardiomyopathies. Circ Res. 1974−35(suppl Ul):ll-196−11−207.
- Wigle E.D., Heimbecker R.O., Cunton R.W. Idiopathic ventricular septal hypertrophy causing muscular subaortic stenosis. Circulation. 1962−26:325−34.
- Wigle E.D., H. Rakowski. Hypertrophic cardiomyopathy: When do you diagnosed midventricular hypertrophy. JACC 1992- 19(3): 525−6.
- Wigle E.D., H. Rakowski, Kimball B.P., et.al. Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circ.-1995−92:1680−1692.
- Wigle E.D., Sasson, Z, et.al. Hypertrophic cardiomyopathy. The importance of the extent of hypertrophy. A review. Prog Cardiovasc Dis. 1985 Jul-Aug., 28(1): 1−83.
- Williams W.G., Wigle E.D., H. Rakowski, et.al. Results of surgery for idiopathig hypertrophic obstructive cardiomyopathy.Circulation. 1987−76(suppl.V):V-l 04−108.
- Yu E.H.C., Omran A.S., Wigle E.D., et.al. Mitral regurgitation in hypertrophic obstructive cardiomyopathy: relationship to obstruction and relief with myectomy. J Am Coll.2000−36:2219−25.